Business Strategy and Real-World Evidence.
Evidence Generation
Rapid and precise process from idea generation to high impact evidence publication.
Data Analysis and Interpretation
Show the full potential of your data through advanced analysis for impactful insights.
Insightful Consulting
Tailored consulting partnership with effective internal and external communication to suit your business needs.
Latest News 2025
2 JULY 2025
RWE Research Results Reverse Low UACR Restriction for SGLT2i
NICE reversed its prior restriction for dapagliflozin in low UACR CKD, a decision originally based on limited data for a high-risk subgroup (non-T2D, low uACR). This shift demonstrates growing trust in high-quality RWE research to resolve uncertainty where RCT data are limited or lacking.

NICE

ESC HF
17 MAY 2025
For the first time describing the cardiorenal disease pathways (HF CKD or CKD HF or simultaneous presentation) to comorbid HF+CKD
Cardiorenal Disease Pathways
EHJ

Suspected de novo heart failure
12 FEBRUARY 2025
This RWE research study (REVOLUTION HF) demonstrated the immediate and high risk of heart failure (HF) hospitalization and death in patients presenting in outpatient care with suspected de novo HF.